Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.